81466-35-5Relevant articles and documents
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex
Argyrou, Argyrides,Bagal, Sharan,Bednarski, Emma,Bloecher, Andrew,Castaldi, M. Paola,Chiarparin, Elisabetta,Code, Erin,Drew, Lisa,Fawell, Stephen,Gao, Ning,Hsu, Jessie Hao-Ru,Jacques, Kelly,Kawatkar, Sameer,O’ Donovan, Daniel H.,Pachl, Fiona,Rasmusson, Timothy,Rawlins, Philip,Read, Jon,Robinson, James,Shen, Minhui,Tomlinson, Ronald,Wilson, David M.,Woods, Haley,Zhu, Xiahui
, p. 41 - 46 (2020)
Deregulation of the PRC2 complex, comprised of the core subunits EZH2, SUZ12, and EED, drives aberrant hypermethylation of H3K27 and tumorigenicity of many cancers. Although inhibitors of EZH2 have shown promising clinical activity, preclinical data sugge
FUNCTIONALIZED DIPHENOLICS AND ABSORBABLE POLYMERS THEREFROM
-
Page/Page column 20, (2008/06/13)
The present invention relates to dephenolic compounds, an example of which is shown below, which are functionalized, and polymers formed from the same. Polymers formed from the functionalized diphenolics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.
Benzyloxy derivatives as MAOB inhibitors
-
Page/Page column 9, (2008/06/13)
The invention relates to compounds of the formula and their pharmaceutically acceptable salts wherein R1, R2, R3, R4, R5, n, m, and o are as defined in the specification. The compounds are selective monoamine oxidase β inhibitors and are useful for the treatment and prevention of Alzheimer's disease and senile dementia, as well as other CNS disorders. The invention also relates to processes for preparing such compounds and pharmaceutical compositions containing them.
